Literature DB >> 14624895

Minimizing prostate brachytherapy-related morbidity.

Gregory S Merrick1, Kent E Wallner, Wayne M Butler.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 14624895     DOI: 10.1016/s0090-4295(03)00558-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  6 in total

1.  Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy.

Authors:  J Taylor Whaley; Lawrence B Levy; David A Swanson; Thomas J Pugh; Rajat J Kudchadker; Teresa L Bruno; Steven J Frank
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-31       Impact factor: 7.038

2.  Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer.

Authors:  Young Dong Yu; Moon Hyung Kang; Chang Il Choi; Hyun Soo Shin; Jong Jin Oh; Dong Soo Park
Journal:  World J Urol       Date:  2016-02-11       Impact factor: 4.226

3.  Serial changes of international prostate symptom score following I-125 prostate brachytherapy.

Authors:  Toshio Ohashi; Atsunori Yorozu; Kazuhito Toya; Shiro Saito; Tetsuo Momma
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

4.  Treatment- and disease-related complications of prostate cancer.

Authors:  Anne R Simoneau
Journal:  Rev Urol       Date:  2006

5.  Radiation treatment for patients with intermediate-risk prostate cancer.

Authors:  David E Greene; Jyoti S Mayadev; Richard K Valicenti
Journal:  Ther Adv Urol       Date:  2012-06

6.  Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer.

Authors:  Einsley-Marie Janowski; Thomas P Kole; Leonard N Chen; Joy S Kim; Thomas M Yung; Brian Timothy Collins; Simeng Suy; John H Lynch; Anatoly Dritschilo; Sean P Collins
Journal:  Front Oncol       Date:  2015-07-03       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.